secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0000950170-25-112949
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026
----------------------------------------------------------------

- Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.
- Timelines for all other pipeline programs remain unchanged.
- Updated corporate presentation posted to company website; no other changes disclosed in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025112949/0000950170-25-112949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025112949/cgem-20250904.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-112949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer